



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.  
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated August 16, 2017**

To,  
National Stock Exchange of India Limited  
Bombay Stock Exchange Limited  
Symbol: NSE: GRANULES; BSE: 532482

**Sub: Receipt of Establishment Inspection Report (EIR) from US FDA -Reg.**

**Ref: Our letter dated 17<sup>th</sup> October 2016 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,

Please be informed that, US FDA has issued Establishment Inspection Report (EIR) for the Gagillapur facility of the Company located at Hyderabad, Telangana, India.


This facility was inspected by US FDA in October 2016 and there were no observations during the inspection. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

**For GRANULES INDIA LIMITED**

*G. Chaitanya*  


**CHAITANYA TUMMALA  
(COMPANY SECRETARY &  
COMPLIANCE OFFICER)**